Agenus announced the appointment of Patricia Carlos as Chief Regulatory, Quality, and Safety Officer; Todd Yancey, MD as Global Clinical Development, Medical Affairs and Commercial Development Advisor.
- Patricia Carlos named Chief Regulatory, Quality, and Safety Officer
- Todd Yancey, MD named Senior Global Clinical Development, Medical Affairs and Commercial Advisor
LEXINGTON, Mass., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of therapeutics designed to activate the immune response to cancers and infections, today announced the appointment of Patricia Carlos as Chief Regulatory, Quality, and Safety Officer; Todd Yancey, MD as Global Clinical Development, Medical Affairs and Commercial Development Advisor.
“Our upcoming worldwide Phase 2 botensilimab “ACTIVATE” programs in MSS colorectal cancer and metastatic melanoma are advancing two important indications based on the robust early clinical activity achieved to date across nine treatment-resistant tumor types,” said Garo Armen, PhD, Chairman and Chief Executive Officer of Agenus. “Patricia and Todd bring extensive experience across all stages of clinical development and commercialization and will be integral to advancing our deep pipeline of checkpoint inhibitors, immune activators, and tumor microenvironment conditioning agents, including botensilimab.”
Patricia Carlos has more than 20 years of regulatory affairs leadership experience, directing programs from investigational new drug application to commercialization. Prior to joining Agenus, Patty served as Senior Vice President of Regulatory and Quality at Arcus Biosciences, where she built out the Regulatory, Quality and Safety functions and led the global regulatory strategy. Prior to Arcus, Patty has held leadership roles at BeiGene, Medivation, Gilead Sciences, and Bayer.
“I am thrilled to join Agenus at a critical point in the acceleration of the botensilimab development programs. The data generated in the early clinical trials of botensilimab study underscore its potential to provide tremendous benefit to patients with cold tumors that do not respond to approved therapies,” said Carlos.
Todd Yancey, MD, has 40 years of combined clinical and industry experience. For the last 20 years, he has held global leadership roles of increasing responsibility in Medical Affairs, Clinical Development, and Product Commercialization. Prior to joining Agenus, Dr. Yancey served as Senior Vice President, Global Medical Affairs and New Market Development at BeiGene, Inc. Prior to his work at BeiGene, Dr. Yancey held senior positions at BioMarin, Medivation, Onyx, Genentech and Amgen.
“After forty years in medicine, it is a tremendous privilege to work with the global and patient-focused team at Agenus supporting the effort to bring forth potentially practice-changing, next-generation immuno-oncology therapeutics for patients,” said Dr. Yancey.
About Agenus
Agenus is a clinical-stage immuno-oncology company focused on the discovery and development of therapies that engage the body’s immune system to fight cancer and infections. The Company’s vision is to expand the patient populations benefiting from cancer immunotherapy by pursuing combination approaches that leverage a broad repertoire of antibody therapeutics, adoptive cell therapies (through its subsidiary MiNK Therapeutics), and adjuvants (through its subsidiary SaponiQx). The Company is equipped with a suite of antibody discovery platforms and a state-of-the-art GMP manufacturing facility with the capacity to support clinical programs. Agenus is headquartered in Lexington, MA. For more information, please visit www.agenusbio.com and our Twitter handle @agenus_bio. Information that may be important to investors will be routinely posted on our website and Twitter.
Forward-Looking Statements
This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements relating to our technologies, therapeutic candidates, and capabilities, for instance, statements regarding therapeutic benefit and efficacy, mechanism of action, potency, durability, and safety and tolerability profile of our therapeutic candidates, both alone and in combination with each other and/or other agents; statements regarding future plans, including research, clinical, regulatory, and commercialization plans; and any other statements containing the words “may,” “believes,” “expects,” “anticipates,” “hopes,” “intends,” “plans,” “will” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, among others, the factors described under the Risk Factors section of our most recent Quarterly Report on Form 10-Q or Annual Report on Form 10-K filed with the Securities and Exchange Commission and available on our website: www.agenusbio.com. Agenus cautions investors not to place considerable reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this press release, and Agenus undertakes no obligation to update or revise the statements, other than to the extent required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.
Contact
Ethan Lovell
Chief External Affairs & Communications Officer
339-927-1763
ethan.lovell@agenusbio.com
